Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.56 |
| ▸ | CCR5 | P51681 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | CCR3 | P51677 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950353 | 0.88 | SLC6A4 (0.59) | SLC6A4SLC6A3CCR5SLC6A2CCR3 | |
| SCHEMBL5777439 | 0.88 | SLC6A4 (0.59) | SLC6A4SLC6A3CCR5SLC6A2CCR3 | |
| SCHEMBL13930611 | 0.79 | CCR3 (0.48) | SLC6A4SLC6A3CCR5CCR3LMNA | |
| SCHEMBL5779319 | 0.78 | CCR5 (0.52) | SLC6A4SLC6A3CCR5SLC6A2CCR3 | |
| SCHEMBL13930995 | 0.76 | EPHX2 (0.56) | SLC6A4SLC6A3CCR5SLC6A2SMN1; SMN2 | |
| SCHEMBL13952187 | 0.75 | EPHX2 (0.55) | CCR5TPSAB1CCR3SMN1; SMN2EPHX2 | |
| SCHEMBL7082519 | 0.74 | GRM7 (0.53) | SLC6A4SLC6A3CCR5SLC6A2 | |
| SCHEMBL6011353 | 0.74 | SLC6A3 (0.47) | SLC6A4SLC6A3CCR5SLC6A2 | |
| SCHEMBL6333237 | 0.73 | CCR3 (0.61) | SLC6A3CCR5SLC6A2CCR3 | |
| SCHEMBL5276400 | 0.73 | EPHX2 (0.59) | CCR3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572683-B1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| US-20060069120-A1 | Novel piperidine derivaties as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
| EP-1572683-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056808-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069120-A1 | Novel piperidine derivaties as modulators of chemokine receptor ccr5 | CCR5, CCR2, CXCR4 | SLC6A4 1617/4885SLC6A3 2242/4885CCR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.